Cell-penetrating peptides: two faces of the same coin

2020 ◽  
Vol 477 (8) ◽  
pp. 1363-1366
Author(s):  
Giovanna Maria Pierantoni ◽  
Simona Paladino
Keyword(s):  
Clinical Trials ◽  
Small Molecules ◽  
Therapeutic Agents ◽  
Cell Penetrating Peptides ◽  
Human Diseases ◽  
Short Peptides ◽  
Preclinical Studies ◽  
Cell Penetrating ◽  
Specific Receptors ◽  
Conjugated Compounds

Cell-penetrating peptides (CPPs) are short peptides able to cross the cellular membranes without any interaction with specific receptors. Thanks to their ability to transport various cargo inside the cells are emerged as powerful therapeutic agents alternative to small molecules. In recent years, numerous preclinical studies provided promising results for the treatment of various human diseases. Several CPP-conjugated compounds are under clinical trials.

Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review

2020 ◽  
Vol 16 ◽  
Author(s):  
Ali Ahmadi ◽  
Hadi Esmaeili Gouvarchin Ghaleh ◽  
Ruhollah Dorostkar ◽  
Mahdieh Farzanehpour ◽  
Masoumeh Bolandian
Keyword(s):  
Genetic Disease ◽  
Control Cell ◽  
Gene Mutations ◽  
Therapeutic Agents ◽  
Cell Penetrating Peptides ◽  
Triggered Release ◽  
New Techniques ◽  
Viral Therapy ◽  
Cell Penetrating ◽  
Cancer Cell Targeting

Abstract:: Cancer is a genetic disease triggered by gene mutations, which control cell growth and their functionality inherited from previous generations. The targeted therapy of some tumors was not especially successful. A host of new techniques can be used to treat aptamer-mediated targeting, cancer immunotherapy, cancer stem cell (CSC) therapy, cell-penetrating peptides (CPPs), hormone therapy, intracellular cancer cell targeting, nanoparticles, and viral therapy. These include chemical-analog conjugation, gene delivery, ligand-receptor-based targeting, prodrug therapies, and triggered release strategies. Virotherapy is a biotechnological technique for turning viruses into therapeutic agents by the reprogramming of viruses to cure diseases. In several tumors, including melanoma, multiple myeloma, bladder cancer, and breast cancer, the oncolytic capacity of oncolytic Coxsackievirus has been studied. The present study aims to assess oncolytic Coxsackievirus and its mechanisms of effect on cancer cells.

Therapeutic delivery using cell-penetrating peptides

2013 ◽  
Vol 5 (3) ◽  
Author(s):  
Rupa R. Sawant ◽  
Niravkumar R. Patel ◽  
Vladimir P. Torchilin
Keyword(s):  
Small Molecules ◽  
Therapeutic Agent ◽  
Intracellular Delivery ◽  
Cell Penetrating Peptides ◽  
Current Status ◽  
Unique Challenge ◽  
Large Molecules ◽  
Therapeutic Delivery ◽  
Cell Penetrating ◽  
Stimuli Sensitive

AbstractIntracellular delivery of promising therapeutic agents as well as nanocarriers presents a unique challenge. However, with the discovery of the cell-penetrating peptides (CPPs), overcoming this obstacle seems more plausible. In many cases, CPPs conjugated with therapeutic agent or therapeutic agent loaded-nanoparticles have shown promising results via increased cellular uptake. In this review, the current status of CPPs for the intracellular delivery of not just potential therapeutic small molecules but also large molecules like peptides, nucleic acids and nanocarriers is discussed. In addition, the design of ‘smart stimuli-sensitive nanocarrier’ to overcome the non-target-specificity of CPPs is also described.

scholarly journals The Role of Animal Models in Evaluating Reasonable Safety and Efficacy for Human Trials of Cell-Based Interventions for Neurologic Conditions

2008 ◽  
Vol 29 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Alan Regenberg ◽  
Debra JH Mathews ◽  
David M Blass ◽  
Hilary Bok ◽  
Joseph T Coyle ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Animal Models ◽  
Regenerative Medicine ◽  
Therapeutic Agents ◽  
Preclinical Studies ◽  
Safety And Efficacy ◽  
Proper Role ◽  
New Treatments ◽  
Gathering Data

Progress in regenerative medicine seems likely to produce new treatments for neurologic conditions that use human cells as therapeutic agents; at least one trial for such an intervention is already under way. The development of cell-based interventions for neurologic conditions (CBI-NCs) will likely include preclinical studies using animals as models for humans with conditions of interest. This paper explores predictive validity challenges and the proper role for animal models in developing CBI-NCs. In spite of limitations, animal models are and will remain an essential tool for gathering data in advance of first-in-human clinical trials. The goal of this paper is to provide a realistic lens for viewing the role of animal models in the context of CBI-NCs and to provide recommendations for moving forward through this challenging terrain.

Viral and Other Cell-Penetrating Peptides as Vectors of Therapeutic Agents in Medicine

2015 ◽  
Vol 354 (1) ◽  
pp. 32-42 ◽  
Author(s):  
Julia Durzyńska ◽  
Łucja Przysiecka ◽  
Robert Nawrot ◽  
Jakub Barylski ◽  
Grzegorz Nowicki ◽  
...  
Keyword(s):  
Therapeutic Agents ◽  
Cell Penetrating Peptides ◽  
Cell Penetrating

P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future

2019 ◽  
Vol 25 (26) ◽  
pp. 2792-2807 ◽  
Author(s):  
Pobitra Borah ◽  
Satyendra Deka ◽  
Raghu Prasad Mailavaram ◽  
Pran Kishore Deb
Keyword(s):  
Clinical Trials ◽  
Biological Activities ◽  
Therapeutic Agents ◽  
Current Status ◽  
Preclinical Studies ◽  
P1 Receptors ◽  
Drug Candidates ◽  
Wide Range ◽  
P1 Receptor ◽  
Novel Therapeutic

Background: Adenosine mediates various physiological and pathological conditions by acting on its four P1 receptors (A1, A2A, A2B and A3 receptors). Omnipresence of P1 receptors and their activation, exert a wide range of biological activities. Thus, its modulation is implicated in various disorders like Parkinson’s disease, asthma, cardiovascular disorders, cancer etc. Hence these receptors have become an interesting target for the researchers to develop potential therapeutic agents. Number of molecules were designed and developed in the past few years and evaluated for their efficacy in various disease conditions. Objective: The main objective is to provide an overview of new chemical entities which have crossed preclinical studies and reached clinical trials stage following their current status and future prospective. Methods: In this review we discuss current status of the drug candidates which have undergone clinical trials and their prospects. Results: Many chemical entities targeting various subtypes of P1 receptors are patented; twenty of them have crossed preclinical studies and reached clinical trials stage. Two of them viz adenosine and regadenoson are approved by the Food and Drug Administration. Conclusion: This review is an attempt to highlight the current status, progress and probable future of P1 receptor ligands which are under clinical trials as promising novel therapeutic agents and the direction in which research should proceed with a view to come out with novel therapeutic agents.

scholarly journals Influence of the Dabcyl group on the cellular uptake of cationic peptides: short oligoarginines as efficient cell-penetrating peptides

Amino Acids ◽  
2021 ◽  
Author(s):  
Ildikó Szabó ◽  
Françoise Illien ◽  
Levente E. Dókus ◽  
Mo’ath Yousef ◽  
Zsuzsa Baranyai ◽  
...  
Keyword(s):  
Cellular Uptake ◽  
Cell Penetrating Peptides ◽  
Antitumor Drugs ◽  
Short Peptides ◽  
Cationic Peptides ◽  
Wide Range ◽  
Cell Penetrating ◽  
Delivery Vehicles ◽  
Direct Delivery ◽  
Diffuse Distribution

AbstractCell-penetrating peptides (CPPs) are promising delivery vehicles. These short peptides can transport wide range of cargos into cells, although their usage has often limitations. One of them is the endosomatic internalisation and thus the vesicular entrapment. Modifications which increases the direct delivery into the cytosol is highly researched area. Among the oligoarginines the longer ones (n > 6) show efficient internalisation and they are well-known members of CPPs. Herein, we describe the modification of tetra- and hexaarginine with (4–((4–(dimethylamino)phenyl)azo)benzoyl) (Dabcyl) group. This chromophore, which is often used in FRET system increased the internalisation of both peptides, and its effect was more outstanding in case of hexaarginine. The modified hexaarginine may enter into cells more effectively than octaarginine, and showed diffuse distribution besides vesicular transport already at low concentration. The attachment of Dabcyl group not only increases the cellular uptake of the cell-penetrating peptides but it may affect the mechanism of their internalisation. Their conjugates with antitumor drugs were studied on different cells and showed antitumor activity.

scholarly journals Oligoalanine helical callipers for cell penetration

2018 ◽  
Vol 54 (50) ◽  
pp. 6919-6922 ◽  
Author(s):  
Marta Pazo ◽  
Marisa Juanes ◽  
Irene Lostalé-Seijo ◽  
Javier Montenegro
Keyword(s):  
Amino Acids ◽  
Rational Design ◽  
Chemical Space ◽  
Cell Penetrating Peptides ◽  
Short Peptides ◽  
Cell Penetration ◽  
Basic Amino Acids ◽  
Cell Penetrating ◽  
Natural Amino Acids

Even for short peptides that are enriched in basic amino acids, the large chemical space that can be spanned by combinations of natural amino acids hinders the rational design of cell penetrating peptides.

scholarly journals Combination of Cell-Penetrating Peptides with Nanoparticles for Therapeutic Application: A Review

Biomolecules ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. 22 ◽  
Author(s):  
Sara Silva ◽  
António Almeida ◽  
Nuno Vale
Keyword(s):  
Small Molecules ◽  
Protein Translocation ◽  
Cell Penetrating Peptides ◽  
Amino Acid Residues ◽  
Therapeutic Application ◽  
New Class ◽  
Wide Range ◽  
Cell Penetrating ◽  
Therapeutic Molecules ◽  
Resistant Strains

Cell-penetrating peptides (CPPs), also known as protein translocation domains, membrane translocating sequences or Trojan peptides, are small molecules of 6 to 30 amino acid residues capable of penetrating biological barriers and cellular membranes. Furthermore, CPP have become an alternative strategy to overcome some of the current drug limitations and combat resistant strains since CPPs are capable of delivering different therapeutic molecules against a wide range of diseases. In this review, we address the recent conjugation of CPPs with nanoparticles, which constitutes a new class of delivery vectors with high pharmaceutical potential in a variety of diseases.

scholarly journals Effects of the properties of short peptides conjugated with cell-penetrating peptides on their internalization into cells

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Ryo Matsumoto ◽  
Mina Okochi ◽  
Kazunori Shimizu ◽  
Kei Kanie ◽  
Ryuji Kato ◽  
...  
Keyword(s):  
Cell Penetrating Peptides ◽  
Short Peptides ◽  
Cell Penetrating

Label-free quantification of cell-penetrating peptide translocation into liposomes

2016 ◽  
Vol 8 (23) ◽  
pp. 4608-4616 ◽  
Author(s):  
Marie-Lise Jobin ◽  
Isabel D. Alves
Keyword(s):  
Small Molecules ◽  
Lipid Membranes ◽  
Cell Penetrating Peptides ◽  
Cell Penetrating Peptide ◽  
Label Free ◽  
Label Free Quantification ◽  
Cell Penetrating ◽  
Free Quantification ◽  
Peptide Translocation

Cell penetrating peptides (CPPs) are small molecules capable of crossing lipid membranes and transporting cargos of varied sizes and nature inside cells.

Sign in / Sign up

Export Citation Format

Share Document